News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.


4/15/2013 10:12:53 AM

FREMONT, Calif., April 15, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today the appointment of Kleanthis G. Xanthopoulos, Ph.D., to its Board of Directors. Dr. Xanthopoulos is President & Chief Executive Officer of Regulus Therapeutics Inc. (NASDAQ: RGLS), a leading company developing microRNA therapeutics.

"I am pleased to welcome Dr. Xanthopoulos as our independent board member," said Vikram Lamba, Chief Executive Officer of Zosano Pharma. "He is a veteran life sciences industry CEO whose extensive healthcare, execution and IPO experience will provide Zosano with valuable insight as we pursue potential public options for financing our extensive clinical development program."

Prior to joining Regulus in 2007, Dr. Xanthopoulos was a managing director of Enterprise Partners Venture Capital. He co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, and remained a Director until its acquisition by Roche. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals), and participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the Board of Directors of the Biotechnology Industry Organization (BIO), Apricus Biosciences, Sente Inc., and a member of the board of BIOCOM, Southern California's life science industry association.

"I am delighted to join the Zosano Board," said Dr. Xanthopoulos. "Zosano's ZP Patch Technology has the potential to provide novel drug delivery solutions for many therapeutic indications and I look forward to working with the other Board members and management team to shape the company's future."

About Zosano Pharma

Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in the field of drug delivery systems. Zosano is developing products using ZP Patch Technology, a novel transdermal delivery technology based on microprojections that provide rapid and efficient systemic delivery in a convenient, needlefree, and painfree system. Zosano is a fully integrated development company with a recently launched cGMP manufacturing capability. The company is developing products with significant commercial potential both independently and in collaboration with strategic partners. Learn more at http://www.zosanopharma.com.

SOURCE Zosano Pharma, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES